Interestingly, it was shown that targeting the KLF6 regulator FOXO1 and EGFR with trifluoperazine hydrochloride, a FOXO1 nuclear export inhibitor, and erlotinib, a small-molecule inhibitor of EGFR signaling, leads to KLF6 re-expression.25 In the future, it would be interesting to test the effect of these drugs, alone or in combination with NF-κB inhibitors, on glioblastoma cell proliferation and invasion, in vitro and in vivo. The gene discussed is EGFR; the disease is glioblastoma.